KR20210031852A - 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 - Google Patents

종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 Download PDF

Info

Publication number
KR20210031852A
KR20210031852A KR1020207025771A KR20207025771A KR20210031852A KR 20210031852 A KR20210031852 A KR 20210031852A KR 1020207025771 A KR1020207025771 A KR 1020207025771A KR 20207025771 A KR20207025771 A KR 20207025771A KR 20210031852 A KR20210031852 A KR 20210031852A
Authority
KR
South Korea
Prior art keywords
adenovirus
inhibitor
cdk4
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207025771A
Other languages
English (en)
Korean (ko)
Inventor
페르 손네 홀름
로만 나우로스
Original Assignee
클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 filed Critical 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨
Priority to KR1020267017074A priority Critical patent/KR20260089640A/ko
Publication of KR20210031852A publication Critical patent/KR20210031852A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207025771A 2018-03-05 2019-03-05 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 Ceased KR20210031852A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267017074A KR20260089640A (ko) 2018-03-05 2019-03-05 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18000210 2018-03-05
EP18000210.7 2018-03-05
PCT/EP2019/000067 WO2019170283A1 (en) 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267017074A Division KR20260089640A (ko) 2018-03-05 2019-03-05 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료

Publications (1)

Publication Number Publication Date
KR20210031852A true KR20210031852A (ko) 2021-03-23

Family

ID=61569019

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207025771A Ceased KR20210031852A (ko) 2018-03-05 2019-03-05 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료
KR1020267017074A Pending KR20260089640A (ko) 2018-03-05 2019-03-05 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267017074A Pending KR20260089640A (ko) 2018-03-05 2019-03-05 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료

Country Status (13)

Country Link
US (1) US20210038661A1 (cg-RX-API-DMAC7.html)
EP (1) EP3762004B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021517119A (cg-RX-API-DMAC7.html)
KR (2) KR20210031852A (cg-RX-API-DMAC7.html)
CN (1) CN112533620B (cg-RX-API-DMAC7.html)
AU (1) AU2019232768B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092907A1 (cg-RX-API-DMAC7.html)
DK (1) DK3762004T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965632T3 (cg-RX-API-DMAC7.html)
FI (1) FI3762004T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064471T2 (cg-RX-API-DMAC7.html)
SG (1) SG11202007873VA (cg-RX-API-DMAC7.html)
WO (1) WO2019170283A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210066635A (ko) * 2019-11-28 2021-06-07 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
PL219321B1 (pl) * 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US9271988B2 (en) * 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210066635A (ko) * 2019-11-28 2021-06-07 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
KR20210154954A (ko) * 2019-11-28 2021-12-21 의료법인 성광의료재단 Prb4를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도
KR20210154955A (ko) * 2019-11-28 2021-12-21 의료법인 성광의료재단 Smpd1를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도
KR20210156258A (ko) * 2019-11-28 2021-12-24 의료법인 성광의료재단 Snora14b를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도
KR20210156259A (ko) * 2019-11-28 2021-12-24 의료법인 성광의료재단 Acly를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도

Also Published As

Publication number Publication date
WO2019170283A8 (en) 2019-11-07
CA3092907A1 (en) 2019-09-12
CN112533620A (zh) 2021-03-19
AU2019232768B2 (en) 2025-12-18
HUE064471T2 (hu) 2024-03-28
EP3762004B1 (en) 2023-09-13
EP3762004A1 (en) 2021-01-13
DK3762004T3 (da) 2023-11-27
AU2019232768A1 (en) 2020-09-03
CN112533620B (zh) 2025-03-28
US20210038661A1 (en) 2021-02-11
SG11202007873VA (en) 2020-09-29
ES2965632T3 (es) 2024-04-16
KR20260089640A (ko) 2026-06-15
RU2020132466A (ru) 2022-04-05
JP2025013934A (ja) 2025-01-28
RU2020132466A3 (cg-RX-API-DMAC7.html) 2022-04-05
WO2019170283A1 (en) 2019-09-12
FI3762004T3 (fi) 2023-12-11
JP2021517119A (ja) 2021-07-15

Similar Documents

Publication Publication Date Title
Zhang et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy
Alonso et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo
JP6072414B2 (ja) 腫瘍選択的e1aおよびe1b変異体
Wang et al. Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44+ gastric cancer cells via attenuating Wnt signaling
JP2025013934A (ja) 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置
US20090270484A1 (en) WWOX Vectors and Uses in Treatment of Cancer
JP2007511211A (ja) アデノウイルスおよびそれをコードしている核酸の新たな使用
JP2007511212A (ja) 新規アデノウイルス、それをコードする核酸及びその使用
US20080089864A1 (en) Adenoviruses mutated in the VA genes for cancer treatment
Holzmüller et al. YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma
JP7834342B2 (ja) 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
Yoo et al. Vaccinia virus‐mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP
RU2811278C2 (ru) Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6
RU2835886C1 (ru) Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента
Wang et al. HSF1 overexpression enhances oncolytic effect of replicative adenovirus
Guo et al. Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate
Srivastava et al. Mode of cell death associated with adenovirus-mediated suicide gene therapy in HNSCC tumor model
Ge et al. A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin
Li et al. microRNA response element‑regulated TIKI2 expression suppresses the tumorigencity of malignant gliomas
Majhen et al. Vincristine-resistant human laryngeal carcinoma cells demonstrate increased Rous sarcoma virus promoter activity
Cabrele et al. 5-Fluorouracil-related enhancement of adenoviral infection is Coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes
Rivera Gonzalez Regulation of the prostate-specific hTGP (TGM4) gene and its potential use for prostate cancer gene therapy
Zhang TALEN-mediated site-specific integration of human CFTR gene by a helper-dependent adenoviral vector
Aguirre The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy
Wang et al. Research HSF1 overexpression enhances oncolytic effect of replicative adenovirus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104